TABLE V.
Factors associated with abstract quality scores
Parameter | Estimatea | p Value | Median quality scoreb |
---|---|---|---|
Meeting | |||
ispor | Ref | 0.3100 | 75.0 |
asco | 1.61 | 82.1 | |
ash | −2.27 | 75.0 | |
Year | |||
1997–2000 | Ref | 0.0014 | 67.9 |
2001–2003 | 3.32 | 73.2 | |
2004–2006 | 6.58 | 76.8 | |
2007–2009 | 8.38 | 78.6 | |
Site | |||
Other | Ref | 0.1034 | 72.3 |
Europe | −0.15 | 76.8 | |
North America | 0.39 | 75.0 | |
Cancer | |||
Other | Ref | 0.0053 | 73.2 |
Breast | 2.28 | 75.9 | |
Gastrointestinal | 3.10 | 75.0 | |
Genitourinary | 4.71 | 78.6 | |
Gynecologic | 0.82 | 64.3 | |
Hematologic | 7.45 | 82.1 | |
Lung | −5.45 | 69.6 | |
Type | |||
Other | Ref | 0.7315 | 79.5 |
cea | −2.19 | 73.2 | |
cma | −3.24 | 75.0 | |
cua | −0.93 | 76.8 |
Beta estimates are presented in this linear regression model.
Abstract scores have been normalized.
ispor = International Society for Pharmacoeconomics and Outcomes Research; Ref = reference variable; asco = American Society of Clinical Oncology; ash = American Society of Hematology; cea = cost-effectiveness analysis; cma = cost-minimization analysis; cua = cost–utility analysis.